[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370097-105":59,"doc-detail-370097-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomic-profiling-of-pediatric-solid-tumors-with-a-dual-dnarna-panel-jccg-top2-study","Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel - JCCG-TOP2 Study","","To develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted with the Japan Children's Cancer Group from January 2022 to February 2023. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0–29 years with solid tumors. Genomic profiling used the TOP2 hybrid capture–enrichment system targeting 737 DNA genes and 455 RNA genes, plus allele-specific copy number alterations. Among 210 enrolled patients, TOP2 findings supported diagnosis of pediatric solid tumors and produced potentially actionable results in most cases.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-profiling-of-pediatric-solid-tumors-with-a-dual-dnarna-panel-jccg-top2-study/370097/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-profiling-of-pediatric-solid-tumors-with-a-dual-dnarna-panel-jccg-top2-study/370097.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the JCCG-TOP2 study?","Question",{"text":112,"@type":113},"To develop an optimized genomic medicine platform for pediatric cancers by conducting nationwide genomic profiling using a dual DNA/RNA panel.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which samples and patient age range were analyzed?",{"text":117,"@type":113},"Matched blood and FFPE tumor samples were analyzed from patients aged 0–29 years with solid tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"What genomic panel technology did the study use?",{"text":121,"@type":113},"The TOP2 hybrid capture–enrichment system, targeting 737 DNA genes and 455 RNA genes, and incorporating allele-specific genome copy number alterations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370097,1790445680,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nGenomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study  \nKayoko Tao1,2,3  | Takako Yoshioka4 | Miho Kato5  | Kazuyuki Komatsu6 | Shinichi Tsujimoto7 |  \nKenichi Sakamoto8 | Kazuki Tanimura1,9 | Minako Sugiyama1,10 | Masahiro Sekiguchi11 | Yoshiko Nakano11,12  | Yoshihiro Otani13  | Yasushi Yatabe14  | Akihiko Yoshida14 | Hajime Okita15 | Junko Hirato16 | Kenichi Kohashi17  | Yukichi Tanaka18 | Shinji Kohsaka3  | Takashi Kubo2,19 | Kuniko Sunami19  | Makoto Hirata12 |  \nShuichi Tsutsumi20 | Hiroyuki Aburatani20 | Katsuyoshi Koh21 | Masahiro Hirayama22 | Shuhei Karakawa23 | Yukayo Terashita10 | Hiroyuki Fujisaki9 | Takeshi Yagi24 | Akihiro Yoneda25,26 | Shinji Mochizuki27 | Hiroyuki Shichino27 | Tatsuya Suzuki28 | Tetsuya Takimoto5 | Koichi Ichimura29,30  | Chitose Ogawa1 | Kimikazu Matsumoto31 | Hitoshi Ichikawa2,32 | Motohiro Kato11,31  \nCorrespondence: Hitoshi Ichikawa ([hichikaw@ncc.go.jp](hichikaw@ncc.go.jp)) | Motohiro Kato ([katom-tky@g.ecc.u-tokyo.ac.jp](katom-tky@g.ecc.u-tokyo.ac.jp))  \nReceived: 8 May 2025 | Revised: 24 September 2025 | Accepted: 30 October 2025  \nFunding: This study was supported by the Japan Health Research Promotion Bureau (Grant 2020-B-02) and the Japan Agency for Medical Research and Development (Grants JP23ck0106876, JP24ck0106870, and JP24ama221415) .  \nKeywords: genomic medicine | integrative diagnosis | molecularly targeted therapy | multigene panel | pediatric cancers  \nABSTRACT  \nTo develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted from January 2022 to February 2023 in collaboration with the Japan Children's Cancer Group. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0–29 years with solid tumors. Genomic analysis used the TOP2 hybrid capture–enrichment system, targeting 737 and 455 genes in the DNA and RNA panels, along with allele-specific genome copy number alterations. A total of 210 patients from 50 institutions were enrolled across Japan (median age, 8 years; range, 0–25). Of these, 154 (77%) were enrolled at diagnosis or during/after initial treatment and 56 (27%) at disease progression or relapse. The TOP2 findings had great benefits in clarifying the diagnosis of pediatric solid tumors. Among the 204 patients with genomic results, 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%), respectively. Oncogenic fusions were noted in 45 (23%) patients. A copy number alteration was identified in at least one genomic region in 170 (83%) patients. Two patients exhibited a high tumor mutation burden. Seventeen (8%) patients harbored a germline pathogenic/likely pathogenic variant in cancer-predisposing genes. This study highlighted the feasibility of implementing a nationwide precision medicine platform and the clinical utility of the TOP2 system for pediatric cancers. The results support the integration of genomic data into the standard clinical care of pediatric patients with cancer, both at diagnosis and at relapse.  \n1 | Introduction  \nAnnually, approximately 3000 children and adolescents aged \u003C 20years are diagnosed with cancer in Japan [1] . Pediatric cancer comprises a broad and heterogeneous range of rare  \ncancers with distinct pathogenesis and molecular characteristics. Inherent diagnostic complexities and limited therapeutic options often compromise patient outcomes, for which comprehensive genomic profiling (CGP) holds immense potential to overcome diagnostic and therapeutic challenges.  \n\n| Abbreviations: CGM, cancer genomic medicine; CGP, comprehensive genomic profiling; FFPE, formalin-fixed paraffin-embedded; JCCG, Japan Children's Cancer Group; MTB, molecular tumor board; PAF, potentially actionable findings; TOP, Todai OncoPanel.\u003Cbr>For affiliations refer to page 533. |\n| --","cbCaivXn50VLR3HG","https://ap.wps.com/l/cbCaivXn50VLR3HG","pdf",2689453,14,"English","# Introduction\n## Study goals and rationale\n## Genomic profiling approach and rationale","[{\"question\":\"What was the purpose of the JCCG-TOP2 study?\",\"answer\":\"To develop an optimized genomic medicine platform for pediatric cancers by conducting nationwide genomic profiling using a dual DNA/RNA panel.\"},{\"question\":\"Which samples and patient age range were analyzed?\",\"answer\":\"Matched blood and FFPE tumor samples were analyzed from patients aged 0–29 years with solid tumors.\"},{\"question\":\"What genomic panel technology did the study use?\",\"answer\":\"The TOP2 hybrid capture–enrichment system, targeting 737 DNA genes and 455 RNA genes, and incorporating allele-specific genome copy number alterations.\"}]","Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel - JCCG-TOP2 Study | PDF",1790186703,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce0ff10ba7e4c4ce4bc50dc62fbe9b93.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3aca873ad8213df4cd1c2803f4f46b7.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfcc64b365bd0179792a924f49ebd523.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43c4b990fb7c929c7ab76b35a5564ead.webp",980,1287]